Targeted further research to identify IGRAs with improved accuracy is strongly encouraged. Such research should be based on adequate study design and including quality principles such as representative suspect populations, prospective follow-up and adequate, explicit blinding. It is also strongly recommended that proof-of-principle studies be followed by evidence produced from prospectively implemented and well designed evaluation and demonstration studies, including assessment of patient impact.
Publication Details
Copyright
All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).
Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).
Publisher
World Health Organization, Geneva
NLM Citation
Use of Tuberculosis Interferon-Gamma Release Assays (IGRAs) in Low- and Middle- Income Countries: Policy Statement. Geneva: World Health Organization; 2011. 6, Implications for further research.